European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026
The European burden of breast cancer in 2022.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Xue, Zhang Chun, Fu Mengxia
Аннотация
BACKGROUND: As one of the most prevalent malignancies affecting European women, breast cancer continues to impose a substantial public health burden. This study utilizes the latest estimates from the Global Cancer Observatory 2022 to quantify this impact across European countries.
METHODS: The age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) per 100,000 person-years were computed through direct age standardization using the Segi-Doll World standard population as a reference. Associations between the Human Development Index (HDI) and disease indicators were evaluated with Pearson's correlation coefficient. Estimates of future burden through 2050 were generated based on projected demographic trends.
RESULTS: In 2022, Europe reported an estimated 557.9 thousand new breast cancer cases and 144.5 thousand deaths. Russian Federation reported the highest incidence (78.8 thousand) and deaths (22.1 thousand). France (metropolitan) had the highest ASIR (105.4/100,000) while Cyprus had the highest ASMR (18.6/100,000). ASMR increased with age, surged in individuals over 75 in Europe. Albania had the earliest ASIR peak age at 45-59 years (142.0/100,000). A positive correlation was observed between HDI and incidence rates. Projections suggest that by 2050, Germany, Russian Federation and France (metropolitan) will bear the highest disease burden, with Luxembourg and Cyprus experiencing over 48 % rise in incidence and 70 % rise in mortality rates.
CONCLUSIONS: Breast cancer remains a major health challenge in Europe, with wide inter-country disparities. Rising incidence and mortality in some Central and Eastern countries underline persistent inequalities, emphasizing the need for coordinated prevention, early detection, and equitable care.
METHODS: The age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) per 100,000 person-years were computed through direct age standardization using the Segi-Doll World standard population as a reference. Associations between the Human Development Index (HDI) and disease indicators were evaluated with Pearson's correlation coefficient. Estimates of future burden through 2050 were generated based on projected demographic trends.
RESULTS: In 2022, Europe reported an estimated 557.9 thousand new breast cancer cases and 144.5 thousand deaths. Russian Federation reported the highest incidence (78.8 thousand) and deaths (22.1 thousand). France (metropolitan) had the highest ASIR (105.4/100,000) while Cyprus had the highest ASMR (18.6/100,000). ASMR increased with age, surged in individuals over 75 in Europe. Albania had the earliest ASIR peak age at 45-59 years (142.0/100,000). A positive correlation was observed between HDI and incidence rates. Projections suggest that by 2050, Germany, Russian Federation and France (metropolitan) will bear the highest disease burden, with Luxembourg and Cyprus experiencing over 48 % rise in incidence and 70 % rise in mortality rates.
CONCLUSIONS: Breast cancer remains a major health challenge in Europe, with wide inter-country disparities. Rising incidence and mortality in some Central and Eastern countries underline persistent inequalities, emphasizing the need for coordinated prevention, early detection, and equitable care.